A Clinical Trial to Confirm Safety & Effectiveness of the SYNERGY 4.50 mm and 5.00 mm Stent for Treatment of Atherosclerotic Lesion(s)

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

May 9, 2019

Primary Completion Date

January 7, 2022

Study Completion Date

November 28, 2023

Conditions
AtherosclerosisHeart Diseases, CoronaryCoronary Artery DiseaseCardiovascular Diseases
Interventions
DEVICE

SYNERGY 4.50 mm and 5.0 mm Coronary Stent System

The SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System), manufactured by BSC, is a device/drug combination product comprised of two regulated components: a device (Coronary Stent System) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).

Trial Locations (9)

22042

Inova Fairfax Hospital, Fairfax

27607

Wake Medical Center, Raleigh

33756

Clearwater Cardiovascular Consultants, Clearwater

45219

Lindner Center for Research and Education at Christ Hospital, Cincinnati

64116

North Kansas City Hospital, Kansas City

75226

Baylor Heart and Vascular Hospital, Dallas

97239

Oregon Health Science University, Portland

06510

Yale New Haven Hospital, New Haven

02215

Beth Israel Deaconness Medical Center, Boston

Sponsors
All Listed Sponsors
lead

Boston Scientific Corporation

INDUSTRY